Trials / Terminated
TerminatedNCT03228576
Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association
Observationnal Multicenter Study on a Prospective Cohort of Kidney Transplanted Patients Receiving a Year After Transplant an Extended Releasing Tacrolimus-Everolimus Association
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 16 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacrolimus by lowering the dosage. The commercialisation of a new extended release Tacrolimus pharmaceutical form and the lack of information justify a modality of use and tolerence evaluation of this new association, commonly used.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Extended release Tacrolimus-Everolimus association | Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus |
Timeline
- Start date
- 2017-04-14
- Primary completion
- 2018-12-18
- Completion
- 2018-12-18
- First posted
- 2017-07-25
- Last updated
- 2019-08-28
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03228576. Inclusion in this directory is not an endorsement.